header image

News

Australia's Therapeutic Goods Administration approves Octapharma’s human cell line recombinant FVIII Nuwiq®

07.11.2014

Lachen, Switzerland, November 7th, 2014: Octapharma is pleased to announce that Australia's Therapeutic Goods Administration has approved Octapharma’s human cell line recombinant FVIII Nuwiq® for the treatment and prophylaxis of...

Health Canada approves Octapharma’s new generation recombinant FVIII (Nuwiq®) for all age groups in haemophilia A

05.11.2014

Lachen, Switzerland, November 5th, 2014: Octapharma Canada announces that Health Canada has approved Nuwiq® (recombinant FVIII) for treatment and prophylaxis of bleeding in patients of all ages suffering with haemophilia A...

European Commission publishes approval of Octapharma’s human cell line recombinant FVIII (Nuwiq®) across all age groups in haemophilia A

05.08.2014

Lachen, Switzerland, August 5th, 2014: The European Commission has published approval of Octapharma’s Nuwiq® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with haemophilia A (congenital...

Octapharma USA Announces FDA Approval of octagam® 10%, expanding its Immune Globulin Therapy Portfolio

17.07.2014

LACHEN, Switzerland, July 17th, 2014: Octapharma USA announce the U.S. Food and Drug Administration (FDA) has approved octagam® 10% [Immune Globulin Intravenous (Human) 10% 100 mg/mL Liquid Preparation] for the treatment of...

Octapharma sponsors symposium “Spotlight on the human factor: building a foundation for the future of haemophilia A management" at 2014 WFH World Congress in Melbourne, Australia

27.05.2014

LACHEN, Switzerland, May 27th, 2014: Octapharma sponsored the symposium "Spotlight on the human factor: building a foundation for the future of haemophilia A management" during the World Federation of Hemophilia (WFH)...

European Medicines Agency (EMA) adopts positive opinion on Octapharma’s human cell line recombinant human FVIII (Nuwiq®) in children and adults with haemophilia A

23.05.2014

Lachen, Switzerland, May 23rd, 2014 – Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing...

Octapharma Group release 2013 Annual Report

28.02.2014

Today the Octapharma Group released its 2013 Annual Report in which it reports net sales of 1.154 billion Euro in 2013, representing an increase of 238 million Euro or 26% compared to the 2012 figure. The significant increase...